Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study
A. Weill(Université Paris Cité), F. Brunet‐Possenti(Inserm), P. Celérier(Centre Hospitalier de La Rochelle), Charlée Nardin(CHU Dijon Bourgogne), V. Descamps(Assistance Publique – Hôpitaux de Paris), Célèste Lebbé(Inserm), A. Dupuy(Université de Rennes), G. Jeudy(CHU Dijon Bourgogne), L. Machet(Université de Tours), E. Maubec(Inserm), F. Aubin(Centre Hospitalier Universitaire de Besançon), Christine Longvert, B. Bonniaud(CHU Dijon Bourgogne), Dimitri Psimaras(Université Claude Bernard Lyon 1), Sarah Léonard-Louis(Assistance Publique – Hôpitaux de Paris), Valentine Heidelberger(Assistance Publique – Hôpitaux de Paris), V. Gounant, Ludovic Doucet(Hôpital Saint-Louis), Gérard Zalcman(Inserm), Yannick Le Corre(Université Nantes Angers Le Mans), Nausicaa Malissen(Icahn School of Medicine at Mount Sinai), Julie Delyon(Inserm), Lydia Deschamps(Université Claude Bernard Lyon 1), Barouyr Baroudjian(Hôpital Saint-Louis), Solenne Brosseau(Université Paris Cité), B. Hervier(Université Paris Cité), Monica Dinulescu(Hôpital Pontchaillou), Adèle de Masson(Hôpital Saint-Louis)
Cited by 30
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k